Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aipalolitoworilimab plus docetaxel in driver gene-negative metastatic NSCLC after failure of first-line chemo-immunotherapy
ChiCTR2600121552Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aipalolitoripalimab in non-small cell lung cancer (NSCLC), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
aipalolitoripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600121552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121552.